{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:07:06Z","timestamp":1791900426676,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-156133"],"award-info":[{"award-number":["PJT-156133"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-198012"],"award-info":[{"award-number":["PJT-198012"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PDI-192183"],"award-info":[{"award-number":["PDI-192183"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019683","name":"Cole Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022706","name":"Cole Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.molmed.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:27:33Z","timestamp":1759793253000},"page":"326-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["BH3 mimetic therapies for CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia"],"prefix":"10.1016","volume":"32","author":[{"given":"Caroline","family":"Capdevielle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"St-Amand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Neault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja A.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-0338","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rick A.","family":"Mallette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.09.006_bb0005","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood.V97.12.3727","article-title":"Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience","volume":"97","author":"Athale","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2025.09.006_bb0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.trecan.2017.07.003","article-title":"Pediatric acute megakaryoblastic leukemia: multitasking fusion proteins and oncogenic cooperations","volume":"3","author":"Lopez","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2025.09.006_bb0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2025.09.006_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.critrevonc.2019.04.011","article-title":"The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children","volume":"138","author":"Masetti","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0045","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2016.119","article-title":"A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"30","author":"Eidenschink Brodersen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2025.09.006_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3\u2013GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.09.006_bb0055","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1084\/jem.20121343","article-title":"Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models","volume":"209","author":"Thiollier","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0060","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2014.106526","article-title":"Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002\/01 protocol have an outcome comparable to that of older children","volume":"99","author":"Masetti","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2025.09.006_bb0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/08880018.2017.1414905","article-title":"Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial","volume":"34","author":"Teyssier","year":"2017","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0070","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.16203","article-title":"Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup","volume":"188","author":"Hara","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0075","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3\u2013GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET pediatric AML study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.09.006_bb0080","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","volume":"89","author":"Hann","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2017.02.006","article-title":"ETO2\u2013GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia","volume":"31","author":"Thirant","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.09.006_bb0090","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","article-title":"CBFA2T3\u2013GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype","volume":"121","author":"Masetti","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0095","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/emboj.2011.500","article-title":"Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence","volume":"31","author":"Fischer","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2025.09.006_bb0100","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/MCB.00404-08","article-title":"Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation","volume":"28","author":"Chyla","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6301385","article-title":"Emerging roles of MTG16 in cell-fate control of hematopoietic stem cells and cancer","volume":"2017","author":"Steinauer","year":"2017","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.molmed.2025.09.006_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.exphem.2012.10.015","article-title":"Role of transcriptional corepressor ETO2 in erythroid cells","volume":"41","author":"Fujiwara","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0115","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1074\/jbc.M108062200","article-title":"Characterization of Glis2, a novel gene encoding a Gli-related, Kr\u00fcppel-like transcription factor with transactivation and repressor functions. Roles in kidney development and neurogenesis","volume":"277","author":"Zhang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.09.006_bb0120","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1128\/MCB.01722-07","article-title":"Kr\u00fcppel-like zinc finger protein Glis2 is essential for the maintenance of normal renal functions","volume":"28","author":"Kim","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1084\/jem.20150806","article-title":"Functional screen identifies regulators of murine hematopoietic stem cell repopulation","volume":"213","author":"Holmfeldt","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113084","article-title":"CBFA2T3\u2013GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax","volume":"42","author":"Neault","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2025.09.006_bb0135","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/2159-8290.CD-18-1463","article-title":"Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia","volume":"9","author":"Lopez","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.09.006_bb0140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/bloodadvances.2022008899","article-title":"CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216","volume":"8","author":"Gress","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.molmed.2025.09.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3\u2013GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.09.006_bb0150","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41467-019-09917-0","article-title":"A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML","volume":"10","author":"Drenberg","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.09.006_bb0155","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.3390\/cancers14204995","article-title":"Targeting apoptosis in AML: where do we stand?","volume":"14","author":"Krawiec","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.09.006_bb0160","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41467-024-53158-9","article-title":"CBFA2T3\u2013GLIS2 mediates transcriptional regulation of developmental pathways through a gene regulatory network","volume":"15","author":"Garfinkle","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.09.006_bb0165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41375-022-01800-0","article-title":"High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia","volume":"37","author":"Aid","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2025.09.006_bb0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.09.006_bb0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0180","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0185","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2025.09.006_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101251","article-title":"Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax","volume":"34","author":"Konopleva","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0200","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41419-019-2203-z","article-title":"BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells","volume":"11","author":"Afreen","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2025.09.006_bb0210","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.3390\/ijms21207591","article-title":"Regulation of platelet production and life span: role of Bcl-xL and potential implications for human platelet diseases","volume":"21","author":"Josefsson","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.09.006_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.97","article-title":"BCL-2 is dispensable for thrombopoiesis and platelet survival","volume":"6","author":"Debrincat","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2025.09.006_bb0220","doi-asserted-by":"crossref","first-page":"8329","DOI":"10.1074\/jbc.M109824200","article-title":"Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways","volume":"277","author":"Kirito","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.09.006_bb0225","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1242\/dev.127.22.4949","article-title":"Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly","volume":"127","author":"Wagner","year":"2000","journal-title":"Development"},{"key":"10.1016\/j.molmed.2025.09.006_bb0230","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0235","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","article-title":"Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a Phase 2a study","volume":"62","author":"de Vos","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molmed.2025.09.006_bb0240","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","article-title":"First-in-human study with preclinical data of BCL-2\/BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors","volume":"30","author":"Lakhani","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.09.006_bb0245","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3324\/haematol.2023.284353","article-title":"LP-118 is a novel B-cell lymphoma 2\/extra-large inhibitor that demonstrates efficacy in models of venetoclax resistant chronic lymphocytic leukemia","volume":"110","author":"Ravikrishnan","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.molmed.2025.09.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0255","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0260","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3390\/cells13221922","article-title":"BCL2i-based therapies and emerging resistance in chronic lymphocytic leukemia","volume":"13","author":"Li","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2025.09.006_bb0265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0270","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2025.09.006_bb0275","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1535-7163.MCT-09-0651","article-title":"Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia\/lymphoma cell lines","volume":"9","author":"Tahir","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2025.09.006_bb0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0285","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.2217\/fon-2021-0262","article-title":"Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia","volume":"17","author":"Othman","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28398","article-title":"Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia","volume":"67","author":"Winters","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.molmed.2025.09.006_bb0295","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/cancers16010073","article-title":"Venetoclax: a game changer in the treatment of younger AML patients?","volume":"16","author":"Molica","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.09.006_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29221","article-title":"Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3\/GLIS2 childhood acute myeloid leukaemia","volume":"68","author":"Mishra","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.molmed.2025.09.006_bb0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41375-024-02400-w","article-title":"Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines","volume":"39","author":"Safa-Tahar-Henni","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2025.09.006_bb0310","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12943-024-02110-y","article-title":"Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia","volume":"23","author":"Alonso-P\u00e9rez","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molmed.2025.09.006_bb0315","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI130189","article-title":"Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes","volume":"130","author":"Meyer","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.09.006_bb0320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(00)81013-2","article-title":"Fetal anemia and apoptosis of red cell progenitors in Stat5a-\/-5b-\/- mice: a direct role for Stat5 in Bcl-XL induction","volume":"98","author":"Socolovsky","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2025.09.006_bb0325","doi-asserted-by":"crossref","first-page":"22165","DOI":"10.1074\/jbc.274.32.22165","article-title":"Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines","volume":"274","author":"Silva","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2025.09.006_bb0330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2025.09.006_bb0335","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4","article-title":"STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells","volume":"78","author":"Zushi","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2025.09.006_bb0340","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"de Rooij","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.molmed.2025.09.006_bb0350","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.molmed.2025.09.006_bb0355","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1101\/gad.276725.115","article-title":"Inactivation of prosurvival Bcl-2 proteins activates Bax\/Bak through the outer mitochondrial membrane","volume":"30","author":"O\u2019Neill","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.molmed.2025.09.006_bb0360","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41418-018-0183-7","article-title":"BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL","volume":"26","author":"Greaves","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.molmed.2025.09.006_bb0365","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.25607.1","article-title":"The third model of Bax\/Bak activation: a Bcl-2 family feud finally resolved?","volume":"9","author":"Luo","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.molmed.2025.09.006_bb0370","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.str.2013.02.024","article-title":"Apoptosome structure, assembly, and procaspase activation","volume":"21","author":"Yuan","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.molmed.2025.09.006_bb0375","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a Phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0380","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.09.006_bb0385","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1182\/blood-2011-03-344812","article-title":"BCL2\/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation","volume":"117","author":"Vogler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0390","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.09.006_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.413","article-title":"Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity","volume":"5","author":"Schmid","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2025.09.006_bb0400","doi-asserted-by":"crossref","first-page":"S759","DOI":"10.1016\/j.annonc.2023.09.2352","article-title":"First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody\u2013drug conjugate combined with osimertinib (OSI) in relapsed\/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"34","author":"Rotow","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.09.006_bb0405","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.09.006_bb0410","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.09.006_bb0415","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.09.006_bb0420","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.09.006_bb0425","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 profiling \u2013 measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Del Gaizo Moore","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.molmed.2025.09.006_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay1451","article-title":"High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors","volume":"13","author":"Bhola","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.molmed.2025.09.006_bb0435","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.09.006_bb0440","first-page":"1253","article-title":"BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics","volume":"109","author":"Pan","year":"2024","journal-title":"Haematologica"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:53:26Z","timestamp":1775696006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1471491425002151"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.09.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BH3 mimetic therapies for CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}